<DOC>
	<DOCNO>NCT02046213</DOCNO>
	<brief_summary>The purpose study determine metabolism excretion [ 14C ] E2006 healthy male subject .</brief_summary>
	<brief_title>An Open-label , Single-dose Study Determine Metabolism Excretion 14CE2006 Healthy Male Subjects</brief_title>
	<detailed_description>This open-label , single-dose study healthy male subject . The study 2 phase : Pretreatment Treatment . The Pretreatment Phase last 21 day consist Screening Period Baseline Period , subject 's eligibility determine assessment conduct .</detailed_description>
	<criteria>Inclusion Criteria 1 . Healthy male 18 55 year , inclusive , time informed consent 2 . Body mass index ( BMI ) 18 32 kg/m2 Screening 3 . Must successful vasectomy ( confirm azoospermia ) female partner must childbearing potential must practice highly effective contraception throughout study period 90 day study drug discontinuation . No sperm donation allow study period 90 day study drug discontinuation . 4 . Provide write informed consent 5 . Willing able comply aspect protocol Exclusion Criteria 1 . Participated 14C research study within 6 month prior Day 2 . The total radiation exposure radiolabelled compound study previous study must within recommend level consider safe ( per US 21 CFR 361.1 ) 2 . Exposure clinically significant radiation ( great 100 milliseiverts ) within 12 month prior Day 2 3 . Any history cerebrovascular disease ( stroke transient ischemic attack ) 4 . A prolonged QT/QTc interval ( QTc great 450 msec ) demonstrate upon confirmatory ECG first ECG indicate prolonged QT/QTc interval 5 . History prolong QT/QTc interval 6 . History risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) use concomitant medication prolong QT/QTc interval 7 . Heart rate le 40 great 100 beats/min Screening Baseline 8 . History ischemic heart disease ( e.g. , acute coronary syndrome , stable angina ) , syncope cardiac arrhythmia 9 . Systolic blood pressure great 140 mmHg less 90 mmHg diastolic blood pressure great 90 mmHg less 60 mmHg Screening Baseline 10 . Hemoglobin le 12.5 g/dL hemotocrit le equal 38 % Baseline checkin 11 . Evidence clinically significant disease ( e.g. , psychiatric disorder , disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system ) opinion investigator ( ) could affect subject 's safety interfere study assessment 12 . Any laboratory abnormality consider clinically significant investigator 13 . Clinically significant illness require medical treatment within 8 week dose clinically significant infection within 4 week dose 14 . Any history gastrointestinal surgery ( e.g. , hepatectomy , nephrotomy , digestive organ resection ) may affect PK profile study drug 15 . Hypersensitivity study drug excipients 16 . Known human immunodeficiency virus ( HIV ) positive positive viral screen HIV viral hepatitis B hepatitis C 17 . History drug alcohol dependency abuse within approximately last 2 year positive urine drug test breath alcohol test Screening Baseline 18 . Do meet restriction concomitant medication , food beverage ( see ) 19 . Use illegal ( legalize ) recreational drug past year 20 . Engagement strenuous exercise within 2 week prior dose ( e.g. , marathon runner , weight lifter ) 21 . Currently enrol another clinical trial use investigational drug device within 30 day precede informed consent Restrictions prior concomitant medication , food beverage 22 . Prescription drug prohibit within 4 week dose overthecounter drug within 2 week prior dose throughout Treatment Period 23 . Smoking use tobacco nicotinecontaining product prohibit within 4 week prior dose throughout Treatment Period 24 . Intake caffeinated beverage food prohibit within 72 hour prior dose 72 hour postdose 25 . Intake nutritional supplement , juice , herbal preparation food beverage may affect CYP3A4 enzyme transporter ( e.g. , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ e.g. , kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard ] charbroiled meat ) prohibit within 2 week prior dose throughout Treatment Period 26 . Intake herbal preparation contain St. John 's Wort prohibit within 4 week prior dose throughout Treatment Period 27 . Any subject know history malaria travel country know malarial risk ( ie , designated 'high ' 'moderate ' risk country accord list available athttp : //www.cdc.gov/malaria ) within last year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metabolism Excretion</keyword>
</DOC>